Cancer vaccine shows early promise in gastric cancer clinical trial
-
Strong immune responses measured in the first patients dosed
-
Dose escalation recommended after no safety, toxicity or tolerability issues
-
Clinical data will guide recommended dose for planned Phase 2 study
MELBOURNE Australia 07 February 2018: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company is pleased to announce its HER-Vaxx cancer vaccine (IMU-131) is showing early promise in patients with metastatic gastric cancer and feedback from clinicians running the study has been positive.
For further information please download PDF attached:
Download this document
